3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004–2013

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Using aggregated data available on the interactive website from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project Network (HCUPnet), we examined the annual volume of invasive aspergillosis (IA)-related hospitalizations in the US.

          Methods

          This was a population study. Age-adjusted volumes were derived through population incidence calculated using year-specific censal and intercensal US population estimates available from the US Census Bureau. We additionally examined IA as the principal diagnosis and its associated outcomes in patients with ICD-9-CM codes 117.3, 117.9 and 484.6.

          Results

          The age-adjusted number of annual hospitalizations with IA grew from 35,968 cases in 2004 to 51,870 in 2013, a 44.2% overall increase, 4.4% per annum. Regionally, the South contributed the plurality of the cases (40%), and the Northeast the fewest (17%). While IA as principal diagnosis dropped, from 14.4 to 9.3%, mortality rose from 10 to 12%. Despite mean hospital length of stay decreasing from 13.3 (standard error [SE] 0.07) to 11.5 (SE 0.6) days, the corresponding mean hospital charges rose from $71,164 (SE $5248) to $123,005 (SE $9738). The aggregate US inflation-adjusted hospital charges for IA principal diagnosis rose from $436,074,445 in 2004 to $592,358,369 in 2013.

          Conclusions

          Given the substantial volume and rate of growth in IA-related hospitalizations in the US between 2004 and 2013, an increase in mortality and high costs, IA may represent an attractive target for intensive preventive efforts.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Laboratory diagnosis of invasive aspergillosis.

          Invasive aspergillosis occurs in a wide range of clinical scenarios, is protean in its manifestations, and is still associated with an unacceptably high mortality rate. Early diagnosis is critical to a favourable outcome, but is difficult to achieve with current methods. Deep tissue diagnostic specimens are often difficult to obtain from critically ill patients. Newer antifungal agents exhibit differential mould activity, thus increasing the importance of establishing a specific diagnosis of invasive aspergillosis. For these reasons, a range of alternate diagnostic strategies have been investigated. Most investigative efforts have focused on molecular and serological diagnostic techniques. The detection of metabolites produced by Aspergillus spp and a range of aspergillus-specific antibodies represent additional, but relatively underused, diagnostic avenues. The detection of galactomannan has been incorporated into diagnostic criteria for invasive aspergillosis, reflecting an increased understanding of the performance, utility, and limitations of this technique. Measurement of (1,3)-beta-D glucan in blood may be useful as a preliminary screening tool for invasive aspergillosis, despite the fact that this antigen can be detected in a number of other fungi. There have been extensive efforts directed toward the detection of Aspergillus spp DNA, but a lack of technical standardisation and relatively poor understanding of DNA release and kinetics continues to hamper the broad applicability of this technique. This review considers the application, utility, and limitations of the currently available and investigational diagnostic modalities for invasive aspergillosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Increase in Adult Clostridium difficile–related Hospitalizations and Case-Fatality Rate, United States, 2000–2005

            Virulence of and deaths from Clostridium difficile–associated disease (CDAD) are on the rise in the United States. The incidence of adult CDAD hospitalizations doubled from 5.5 cases per 10,000 population in 2000 to 11.2 in 2005, and the CDAD-related age-adjusted case-fatality rate rose from 1.2% in 2000 to 2.2% in 2004.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Clostridium difficile Infections among Hospitalized Children, United States, 1997–2006

              The epidemiology of Clostridium difficile infection (CDI) has been shifting over the past decade. Since 2000, the molecular evolution of the hypervirulent toxigenic bacterial strain BI/NAP1/027, which causes severe disease in massive outbreak settings, has been well documented ( 1 – 4 ). Furthermore, the increasing detection of this strain in the United States and other countries coincides with reports of increasing hospitalizations either resulting from or complicated by CDI and associated with increased case-fatality rates ( 5 – 7 ). Although in the past it was not thought to affect pediatric populations substantially, CDI has more recently been implicated as an increasingly prevalent diarrheal pathogen in children ( 8 – 10 ). Moreover, evidence suggests that a large proportion of pediatric CDI cases are community-acquired infections and that many of these infections lack the traditional risk factor of exposure to antimicrobial drugs ( 11 – 13 ). These changes in the epidemiology of pediatric CDI, although not definitively caused by the BI/NAP1/027 strain, are likely related to this strain because at least 2 reports suggest a high prevalence (10%–38%) of this strain in pediatric CDI populations and a 4× increase in complication rates associated with this strain compared with other strains ( 14 , 15 ). Current age-specific epidemiology of CDI among children remains poorly studied. Literature predating the emergence of the epidemic strain suggests that although up to 67% of all neonates (i.e., 1 data source potentially indicates a higher chance of accuracy. In addition, the format in which we analyzed 1 of the databases (Kids’ Inpatient Database [KID]) did not enable separating newborn discharges (defined as those hospitalizations during which the child was born) from those of other children 55 years on a maternal record, and mixed neonatal and maternal records), i.e., no chart reviews are undertaken by the agency. For the current study, all data were derived in aggregate from the publicly available HCUPNet website ( 18 ). Because the years for which data were available were 1997, 2000, 2003, and 2006, our observations were limited to these periods. We examined the annual incidence of CDI-related hospitalizations on the basis of the International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM), code 008.45 (intestinal infection with C. difficile) as a proportion of all hospitalizations. We additionally determined the time trends for CDI as the principal discharge diagnosis in this population. Finally, to understand better the context of increasing CDI-related hospitalizations, we examined trends in hospitalizations related to other diarrheal diseases, specifically Salmonella (ICD-9-CM 00.30), rotavirus (ICD-9-CM 008.61), viral enteritis (ICD-9-CM 008.8), and other infectious enteritides (ICD-9-CM codes 009.0–009.3, 487.8). The second analysis was a cross-sectional characterization of all CDI hospitalizations for patients 80% of all hospitalized children <1 year of age in the HCUP and KID databases. We could not determine whether the relatively high rate of CDI-related hospitalizations among non-newborn infants represents predominantly true disease or colonization. Although more specific than recovery of a toxin-producing strain from culture, even the detection of free toxins A, B, or both in the stool of a symptomatic infant does not ensure a pathogenic role for C. difficile, especially if another cause for diarrhea can be identified. Rates of hospitalizations for rotavirus infections have exhibited a similar increase as those with CDI between 1997 and 2006. Although 2 recent analyses of discharge data for adults suggest that non-CDI causes of diarrhea are not likely leading to a reporting bias as the explanation for the observed increase in CDI rates ( 22 , 23 ), the situation may be different for children in whom rotavirus is a serious pathogen and related hospitalizations are clearly increasing. Although Kim et al. did not report an increase in the frequency of testing for C. difficile in their study, our findings implicate this finding as a distinct possibility that needs to be investigated further ( 9 ). Our study has several limitations. First, case identification was based on administrative coding, thus predisposing to misclassification. However, the degree of misclassification may not be substantial because multiple studies have shown the ICD-9-CM code 008.45 to be a relatively accurate way to identify CDI ( 24 – 26 ). Second, because we had no clinical data available, we could not distinguish stool colonization from CDI infection. Third, we were unable to distinguish community-acquired from healthcare-associated disease. However, our study has several strengths. Because we explored 2 databases and discovered results that are highly consistent not only with each other but with those of previous recent investigations, we have augmented the accuracy of estimates of pediatric CDI incidence ( 9 ). In addition, our data are generalizable to most US-based institutions that care for the pediatric populations. This generalizability sets our results apart from those reported previously because they were limited to the highly specialized setting of children’s hospitals ( 8 , 9 , 11 ). In summary, the incidence of CDI in the pediatric population appears to be increasing in US hospitals. A reporting bias for diarrheal diseases may play a role in this trend given the concomitant increase in rotavirus-related hospitalizations we identified. Future data may clarify this finding because widespread immunization with available rotavirus vaccines may soon lead to reduced incidence of related hospitalizations. The low incidence of CDI-related hospitalizations among newborns reflects current recommendations against routine testing and may support the concept that C. difficile does not cause disease among neonates. In contrast, the relatively high rate of CDI-related hospitalizations among non-newborn infants indicates an urgent need for studies to determine how often C. difficile causes true disease in this population.
                Bookmark

                Author and article information

                Contributors
                (413)-268-6381 , evimedgroup@gmail.com
                rharrington113@gmail.com
                james.spalding@astellas.com
                andrew.shorr@gmail.com
                Journal
                BMC Public Health
                BMC Public Health
                BMC Public Health
                BioMed Central (London )
                1471-2458
                17 May 2019
                17 May 2019
                2019
                : 19
                : 591
                Affiliations
                [1 ]EviMed Research Group, LLC, PO Box 303, Goshen, MA 01032 USA
                [2 ]ISNI 0000 0004 0507 1326, GRID grid.423286.9, Astellas Pharma Global Development, Inc., ; Northbrook, IL USA
                [3 ]ISNI 0000 0000 8585 5745, GRID grid.415235.4, Washington Hospital Center, ; Washington, DC USA
                Article
                6932
                10.1186/s12889-019-6932-9
                6525423
                31101036
                764755e8-4bfc-4ef8-8d34-e2e7a7e55f8d
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 7 March 2018
                : 1 May 2019
                Funding
                Funded by: Astellas Pharma Global Development, Inc., Northbrook, IL, US.
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2019

                Public health
                population study,hcupnet,united states,hospitalizations,invasive aspergillosis,mortality,cost

                Comments

                Comment on this article